Alex Denner, the former head of health-care investments for billionaire Carl Icahn, joined the activist slate challenging drugmaker Vivus Inc. in the first move of his new fund, Sarissa Capital Management LP.
Teva Pharmaceutical Industries Ltd., which just two years ago was analysts’ highest-rated stock among the world’s 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.
Royalty Pharma, an investor in royalty streams from pharmaceuticals, raised its offer to buy Elan Corp. by 12 percent to $6.4 billion after the Irish drugmaker made acquisitions to boost revenue and resist the bid.
Roche Holding AG’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
The introduction of Biogen Idec Inc.’s multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis AG and Sanofi, suggesting the treatment may beat estimates for the year.